111 related articles for article (PubMed ID: 16421225)
1. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats.
Odenwald T; Nakagawa K; Hadtstein C; Roesch F; Gohlke P; Ritz E; Schaefer F; Schmitt CP
J Am Soc Nephrol; 2006 Mar; 17(3):655-62. PubMed ID: 16421225
[TBL] [Abstract][Full Text] [Related]
2. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol.
Lopez I; Aguilera-Tejero E; Mendoza FJ; Almaden Y; Perez J; Martin D; Rodriguez M
J Am Soc Nephrol; 2006 Mar; 17(3):795-804. PubMed ID: 16467452
[TBL] [Abstract][Full Text] [Related]
3. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats.
Piecha G; Kokeny G; Nakagawa K; Koleganova N; Geldyyev A; Berger I; Ritz E; Schmitt CP; Gross ML
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F748-57. PubMed ID: 18199601
[TBL] [Abstract][Full Text] [Related]
4. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
[TBL] [Abstract][Full Text] [Related]
5. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia.
Koleganova N; Piecha G; Ritz E; Schmitt CP; Gross ML
Kidney Int; 2009 Jan; 75(1):60-71. PubMed ID: 19092814
[TBL] [Abstract][Full Text] [Related]
6. Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats.
Amann K; Gassmann P; Buzello M; Orth SR; Törnig J; Gross ML; Magener A; Mall G; Ritz E
Kidney Int; 2000 Jul; 58(1):153-61. PubMed ID: 10886560
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors.
Ogata H; Ritz E; Odoni G; Amann K; Orth SR
J Am Soc Nephrol; 2003 Apr; 14(4):959-67. PubMed ID: 12660330
[TBL] [Abstract][Full Text] [Related]
8. Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats.
Dikow R; Wasserhess C; Zimmerer K; Kihm LP; Schaier M; Schwenger V; Hardt S; Tiefenbacher C; Katus H; Zeier M; Gross LM
Basic Res Cardiol; 2009 Sep; 104(5):571-9. PubMed ID: 19288152
[TBL] [Abstract][Full Text] [Related]
9. Effects of calcimimetic combined with an angiotensin-converting enzyme inhibitor on uremic cardiomyopathy progression.
Mizobuchi M; Ogata H; Hosaka N; Kumata C; Nakazawa A; Kondo F; Koiwa F; Kinugasa E; Akizawa T
Am J Nephrol; 2011; 34(3):256-67. PubMed ID: 21791922
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
Wolf SC; Sauter G; Risler T; Brehm BR
Ren Fail; 2005; 27(4):465-74. PubMed ID: 16060137
[TBL] [Abstract][Full Text] [Related]
11. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat.
Kuhlmann A; Haas CS; Gross ML; Reulbach U; Holzinger M; Schwarz U; Ritz E; Amann K
Am J Physiol Renal Physiol; 2004 Mar; 286(3):F526-33. PubMed ID: 14600034
[TBL] [Abstract][Full Text] [Related]
12. Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic.
Koleganova N; Piecha G; Ritz E; Bekeredjian R; Schirmacher P; Schmitt CP; Gross ML
Lab Invest; 2009 May; 89(5):520-30. PubMed ID: 19188910
[TBL] [Abstract][Full Text] [Related]
13. The calcimimetic R-568 prevents podocyte loss in uninephrectomized ApoE-/- mice.
Gut N; Piecha G; Pradel A; Geldyyev A; Potemkina A; Ritz E; Regele H; Schmitt CP; Gross-Weissmann ML
Am J Physiol Renal Physiol; 2013 Aug; 305(3):F277-85. PubMed ID: 23698122
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Lebel M; Rodrigue ME; Agharazii M; Larivière R
Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
[TBL] [Abstract][Full Text] [Related]
15. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH.
Amann K; Törnig J; Flechtenmacher C; Nabokov A; Mall G; Ritz E
Nephrol Dial Transplant; 1995 Nov; 10(11):2043-8. PubMed ID: 8643165
[TBL] [Abstract][Full Text] [Related]
16. Prevention of uremic bone disease using calcimimetic compounds.
Olgaard K; Lewin E
Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of the brain renin-angiotensin system in rats with chronic renal failure.
Nishimura M; Takahashi H; Yoshimura M
Acta Physiol (Oxf); 2007 Apr; 189(4):369-77. PubMed ID: 17367405
[TBL] [Abstract][Full Text] [Related]
18. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia.
Amann K; Törnig J; Kugel B; Gross ML; Tyralla K; El-Shakmak A; Szabo A; Ritz E
Kidney Int; 2003 Apr; 63(4):1296-301. PubMed ID: 12631346
[TBL] [Abstract][Full Text] [Related]
19. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats.
Schmitt CP; Hessing S; Oh J; Weber L; Ochlich P; Mehls O
Kidney Int; 2000 Apr; 57(4):1484-92. PubMed ID: 10760084
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.
Mizobuchi M; Morrissey J; Finch JL; Martin DR; Liapis H; Akizawa T; Slatopolsky E
J Am Soc Nephrol; 2007 Jun; 18(6):1796-806. PubMed ID: 17513326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
